These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22450799)

  • 1. Improved immune response to recombinant influenza nucleoprotein formulated with ISCOMATRIX.
    Cargnelutti DE; Sanchez MV; Alvarez P; Boado L; Glikmann G; Mattion N; Scodeller EA
    J Microbiol Biotechnol; 2012 Mar; 22(3):416-21. PubMed ID: 22450799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge.
    Gao X; Wang W; Li Y; Zhang S; Duan Y; Xing L; Zhao Z; Zhang P; Li Z; Li R; Wang X; Yang P
    Antiviral Res; 2013 Apr; 98(1):4-11. PubMed ID: 23416215
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic Toll-like receptor 4 (TLR4) and TLR7 ligands as influenza virus vaccine adjuvants induce rapid, sustained, and broadly protective responses.
    Goff PH; Hayashi T; Martínez-Gil L; Corr M; Crain B; Yao S; Cottam HB; Chan M; Ramos I; Eggink D; Heshmati M; Krammer F; Messer K; Pu M; Fernandez-Sesma A; Palese P; Carson DA
    J Virol; 2015 Mar; 89(6):3221-35. PubMed ID: 25568203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local immune responses following nasal delivery of an adjuvanted influenza vaccine.
    Scheerlinck JP; Gekas S; Yen HH; Edwards S; Pearse M; Coulter A; Sutton P
    Vaccine; 2006 May; 24(18):3929-36. PubMed ID: 16540213
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single dose intranasal immunization with ISCOMATRIX vaccines to elicit antibody-mediated clearance of influenza virus requires delivery to the lower respiratory tract.
    Sanders MT; Deliyannis G; Pearse MJ; McNamara MK; Brown LE
    Vaccine; 2009 Apr; 27(18):2475-82. PubMed ID: 19368789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant virus-like particles elicit protective immunity against avian influenza A(H7N9) virus infection in ferrets.
    Liu YV; Massare MJ; Pearce MB; Sun X; Belser JA; Maines TR; Creager HM; Glenn GM; Pushko P; Smith GE; Tumpey TM
    Vaccine; 2015 Apr; 33(18):2152-8. PubMed ID: 25772674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of conserved recombinant proteins (NP & 3M2e) formulated with Alum protected BALB/c mice against influenza A/PR8/H1N1 virus challenge.
    Forqani M; Hosseini SM; Farahmand B; Saleh M; Shokouhi H; Torabi A; Fotouhi F
    Biotechnol Lett; 2021 Nov; 43(11):2137-2147. PubMed ID: 34491470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. New Wisdom to Defy an Old Enemy: Summary from a scientific symposium at the 4th Influenza Vaccines for the World (IVW) 2012 Congress, 11 October, Valencia, Spain.
    Poland GA; Fleming DM; Treanor JJ; Maraskovsky E; Luke TC; Ball EM; Poland CM
    Vaccine; 2013 Apr; 31 Suppl 1():A1-20. PubMed ID: 23587330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
    Altstein AD; Gitelman AK; Smirnov YA; Piskareva LM; Zakharova LG; Pashvykina GV; Shmarov MM; Zhirnov OP; Varich NP; Ilyinskii PO; Shneider AM
    Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential activities of alpha/beta IFN subtypes against influenza virus in vivo and enhancement of specific immune responses in DNA vaccinated mice expressing haemagglutinin and nucleoprotein.
    James CM; Abdad MY; Mansfield JP; Jacobsen HK; Vind AR; Stumbles PA; Bartlett EJ
    Vaccine; 2007 Feb; 25(10):1856-67. PubMed ID: 17240000
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.
    Zheng M; Liu F; Shen Y; Wang S; Xu W; Fang F; Sun B; Xie Z; Chen Z
    Hum Vaccin Immunother; 2015; 11(2):397-406. PubMed ID: 25607884
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lactococcus lactis displayed neuraminidase confers cross protective immunity against influenza A viruses in mice.
    Lei H; Peng X; Zhao D; Ouyang J; Jiao H; Shu H; Ge X
    Virology; 2015 Feb; 476():189-195. PubMed ID: 25546254
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines.
    Drane D; Gittleson C; Boyle J; Maraskovsky E
    Expert Rev Vaccines; 2007 Oct; 6(5):761-72. PubMed ID: 17931156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative studies of infectivity, immunogenicity and cross-protective efficacy of live attenuated influenza vaccines containing nucleoprotein from cold-adapted or wild-type influenza virus in a mouse model.
    Isakova-Sivak I; Korenkov D; Smolonogina T; Tretiak T; Donina S; Rekstin A; Naykhin A; Shcherbik S; Pearce N; Chen LM; Bousse T; Rudenko L
    Virology; 2017 Jan; 500():209-217. PubMed ID: 27829176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancement of Th1 immune responses to recombinant influenza nucleoprotein by Ribi adjuvant.
    Cargnelutti DE; Sanchez MA; Alvarez P; Boado L; Mattion N; Scodeller EA
    New Microbiol; 2013 Apr; 36(2):145-51. PubMed ID: 23686120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Protection against influenza H7N9 virus challenge with a recombinant NP-M1-HSP60 protein vaccine construct in BALB/c mice.
    Yang P; Wang W; Gu H; Li Z; Zhang K; Wang Z; Li R; Duan Y; Zhang S; Wang X
    Antiviral Res; 2014 Nov; 111():1-7. PubMed ID: 25173575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IRES-based co-expression of influenza virus conserved genes can promote synergistic antiviral effects both in vitro and in vivo.
    Khodamoradi S; Shenagari M; Kheiri MT; Sabahi F; Jamali A; Heidari A; Ashrafkhani B
    Arch Virol; 2018 Apr; 163(4):877-886. PubMed ID: 29270718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity.
    Ohba K; Yoshida S; Zahidunnabi Dewan M; Shimura H; Sakamaki N; Takeshita F; Yamamoto N; Okuda K
    Vaccine; 2007 May; 25(21):4291-300. PubMed ID: 17403560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein.
    Epstein SL; Kong WP; Misplon JA; Lo CY; Tumpey TM; Xu L; Nabel GJ
    Vaccine; 2005 Nov; 23(46-47):5404-10. PubMed ID: 16011865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.